Literature DB >> 21785441

Potential for targeted therapy in prostate cancers with ERG abnormalities.

Sean R Williamson1, Liang Cheng.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21785441      PMCID： PMC3739554          DOI： 10.1038/aja.2011.100

Source DB:  PubMed          Journal:  Asian J Androl        ISSN： 1008-682X            Impact factor:   3.285


× No keyword cloud information.
  21 in total

Review 1.  Transcription factors as targets for cancer therapy.

Authors:  James E Darnell
Journal:  Nat Rev Cancer       Date:  2002-10       Impact factor: 60.716

2.  ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin.

Authors:  Sean R Williamson; Shaobo Zhang; Jorge L Yao; Jiaoti Huang; Antonio Lopez-Beltran; Steven Shen; Adeboye O Osunkoya; Gregory T MacLennan; Rodolfo Montironi; Liang Cheng
Journal:  Mod Pathol       Date:  2011-04-15       Impact factor: 7.842

3.  Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications.

Authors:  Juan-Miguel Mosquera; Sven Perner; Elizabeth M Genega; Martin Sanda; Matthias D Hofer; Kirsten D Mertz; Pamela L Paris; Jeff Simko; Tarek A Bismar; Gustavo Ayala; Rajal B Shah; Massimo Loda; Mark A Rubin
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

Review 4.  Recurrent gene fusions in prostate cancer.

Authors:  Chandan Kumar-Sinha; Scott A Tomlins; Arul M Chinnaiyan
Journal:  Nat Rev Cancer       Date:  2008-06-19       Impact factor: 60.716

5.  Complex patterns of ETS gene alteration arise during cancer development in the human prostate.

Authors:  J Clark; G Attard; S Jhavar; P Flohr; A Reid; J De-Bono; R Eeles; P Scardino; J Cuzick; G Fisher; M D Parker; C S Foster; D Berney; G Kovacs; C S Cooper
Journal:  Oncogene       Date:  2007-10-08       Impact factor: 9.867

Review 6.  ETS gene fusions in prostate cancer: from discovery to daily clinical practice.

Authors:  Scott A Tomlins; Anders Bjartell; Arul M Chinnaiyan; Guido Jenster; Robert K Nam; Mark A Rubin; Jack A Schalken
Journal:  Eur Urol       Date:  2009-04-24       Impact factor: 20.096

7.  Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.

Authors:  Brett S Carver; Jennifer Tran; Anuradha Gopalan; Zhenbang Chen; Safa Shaikh; Arkaitz Carracedo; Andrea Alimonti; Caterina Nardella; Shohreh Varmeh; Peter T Scardino; Carlos Cordon-Cardo; William Gerald; Pier Paolo Pandolfi
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

8.  Characterization of ETS gene aberrations in select histologic variants of prostate carcinoma.

Authors:  Bo Han; Rohit Mehra; Khalid Suleman; Scott A Tomlins; Lei Wang; Nishi Singhal; Katherine A Linetzky; Nallasivam Palanisamy; Ming Zhou; Arul M Chinnaiyan; Rajal B Shah
Journal:  Mod Pathol       Date:  2009-05-22       Impact factor: 7.842

9.  Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis.

Authors:  Jennifer C King; Jin Xu; John Wongvipat; Haley Hieronymus; Brett S Carver; David H Leung; Barry S Taylor; Chris Sander; Robert D Cardiff; Suzana S Couto; William L Gerald; Charles L Sawyers
Journal:  Nat Genet       Date:  2009-04-26       Impact factor: 38.330

10.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Authors:  Peter C Fong; David S Boss; Timothy A Yap; Andrew Tutt; Peijun Wu; Marja Mergui-Roelvink; Peter Mortimer; Helen Swaisland; Alan Lau; Mark J O'Connor; Alan Ashworth; James Carmichael; Stan B Kaye; Jan H M Schellens; Johann S de Bono
Journal:  N Engl J Med       Date:  2009-06-24       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.